

IN THE CLAIMS

Claims 1 to 4 and 6 to 8 remain in the application. Claims 4 and 6 are amended.
Claim 5 has been cancelled.

Please amend claim 4 by deleting "for the treatment of disorders responsive to opening of KCNQ potassium channels".


Please cancel claim 5.

Please amend claim 6 by deleting "The method of claim 5" and replace with "A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof.". Please delete "and neurodegenerative disorders" and replace with ", which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1". Please also insert "and" in claim 6, line 17, between "anxiety" and "depression".

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Original) A compound of Formula I or a pharmaceutically acceptable salt thereof



wherein

R is C₁₋₄ alkyl, CF₃ or hydroxymethyl;


R¹ and R² are each independently hydrogen, C₁₋₄ alkyl, halogen or morpholin-4-yl;

R⁴ is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C₁₋₄ alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R⁵ is hydrogen or fluoro; or R⁴ and R⁵ taken together are -CH=CH-CH=CH- or -CH₂CH₂O-; and

R³, R⁶ and R⁷ are each independently selected from hydrogen or fluoro.

2. (Original) The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



wherein

R is methyl or hydroxymethyl;

R¹ and R² are each independently hydrogen, C₁₋₄ alkyl, halogen or morpholin-4-yl;

R⁴ is selected from the group consisting of optionally substituted morpholin-4-yl,

pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C₁₋₄alkyl, dimethylamino, hydroxymethyl, chloro and fluoro;

R⁵ is hydrogen or fluoro; or R⁴ and R⁵ taken together are -CH=CH-CH=CH- or -CH₂CH₂O-; and

R³, R⁶ and R⁷ are each independently selected from hydrogen or fluoro.

3. (Original) The compound of claim 1 selected from the group consisting of:
 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;
 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide;
 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide ;
 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;
 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;
 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (2-hydroxy-1-naphthalen-2-yl-ethyl)-amide;

2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid (1-naphthalen-2-yl-ethyl)-amide;

2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(3-dimethylamino-pyrrolidin-1-yl)-phenyl]-ethyl}-amide;

2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;

2-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;

(S)-2-phenyl-cyclopropanecarboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;

(S)-2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;

(S)-2-phenyl-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; and

(S)-2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid {1-[3-(2-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide;

or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.
5. (Cancelled)
6. (Currently Amended) The method of claims 5- A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof wherein said disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety[L] and depression and neurodegenerative disorders. which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1.
7. (Original) The method of claim 6 wherein said disorder is migraine.
8. (Original) The method of claim 6 wherein said disorder is neuropathic pain.